TL;DR
The CEO of Dr Reddy’s Laboratories warned on Friday that President Trump’s proposed tariffs on imported generic drugs will raise prices for U.S. patients – a direct reversal of the cost-savings that generics provide over brand-name alternatives. The warning comes as generic drugs account for nearly 90% of all U.S. prescriptions, meaning even a modest tariff could ripple across the entire healthcare system.
What Happened
Dr Reddy’s Laboratories CEO issued a stark warning on CNBC on Friday, July 24, 2026, stating that the Trump administration’s proposed tariffs on imported generic drugs will inevitably push up prices for American patients. The comment landed at a moment when the U.S. generic drug supply is already stretched thin by rising raw material costs and regulatory pressures, and it injects fresh uncertainty into the nation’s most relied-upon source of affordable medication.
Key Facts
- Dr Reddy’s is one of India’s largest generic drug manufacturers, with annual revenue exceeding $3 billion and roughly 40% of that coming from North America.
- The company’s CEO made the warning in a CNBC interview on Friday, July 24, 2026, directly attributing the expected price hikes to Trump’s tariff proposal.
- Generic drugs now account for more than 90% of all prescriptions dispensed in the United States, according to the Generic Pharmaceutical Association.
- The U.S. imports nearly 80% of its active pharmaceutical ingredients (APIs) from overseas, with India and China supplying the majority of that volume.
- Dr Reddy’s operates seven FDA-inspected manufacturing plants in India and is one of the largest suppliers of generic drugs to the U.S. market by prescription volume.
- The proposed tariffs are part of a broader “Buy American” trade policy push that has already imposed duties on steel, aluminum, and select electronics.
- Trade analysts estimate that a 10% tariff on generic medicines alone could add $8–12 billion annually to U.S. healthcare costs – a figure the CEO’s warning effectively endorsed.
Breaking It Down
The core logic behind Dr Reddy’s warning is simple: tariffs are a tax at the border, and the U.S. generic drug industry operates on razor-thin margins. Most Indian generic manufacturers – including Dr Reddy’s, Sun Pharma, and Aurobindo – earn net profit margins of 8%–15% on U.S. sales. A 10% tariff would immediately erode those margins, leaving companies with two stark choices: absorb the cost and see profits vanish, or pass the increase down the supply chain. Given that U.S. pharmacy benefit managers and insurers already exert intense pricing pressure, the most likely outcome is that the higher costs land squarely on patients.
“A 10% tariff on generic drugs could wipe out the entire profit margin for a typical Indian manufacturer in the U.S. market,” according to a 2025 analysis by the Brookings Institution’s health policy program. If that happens, companies will either raise wholesale prices or
